Literature DB >> 34161253

Polygenic Risk Scores have high diagnostic capacity in ankylosing spondylitis.

Zhixiu Li1, Xin Wu2, Huji Xu3,4,5, Matthew A Brown6,7, Paul J Leo1, Erika De Guzman8, Nurullah Akkoc9, Maxime Breban10,11,12, Gary J Macfarlane13,14, Mahdi Mahmoudi15, Helena Marzo-Ortega16,17, Lisa K Anderson8, Lawrie Wheeler8, Chung-Tei Chou18,19, Andrew A Harrison20, Simon Stebbings21, Gareth T Jones13,14, So-Young Bang22, Geng Wang23, Ahmadreza Jamshidi15, Elham Farhadi15, Jing Song2, Li Lin2, Mengmeng Li2, James Cheng-Chung Wei24,25,26, Nicholas G Martin27, Margaret J Wright28, MinJae Lee29, Yuqin Wang30, Jian Zhan31, Jin-San Zhang32,33, Xiaobing Wang34, Zi-Bing Jin35, Michael H Weisman36, Lianne S Gensler37, Michael M Ward38, Mohammad Hossein Rahbar39, Laura Diekman40, Tae-Hwan Kim22, John D Reveille40, Bryan Paul Wordsworth41.   

Abstract

OBJECTIVE: We sought to test the hypothesis that Polygenic Risk Scores (PRSs) have strong capacity to discriminate cases of ankylosing spondylitis (AS) from healthy controls and individuals in the community with chronic back pain.
METHODS: PRSs were developed and validated in individuals of European and East Asian ethnicity, using data from genome-wide association studies in 15 585 AS cases and 20 452 controls. The discriminatory values of PRSs in these populations were compared with other widely used diagnostic tests, including C-reactive protein (CRP), HLA-B27 and sacroiliac MRI.
RESULTS: In people of European descent, PRS had high discriminatory capacity with area under the curve (AUC) in receiver operator characteristic analysis of 0.924. This was significantly better than for HLA-B27 testing alone (AUC=0.869), MRI (AUC=0.885) or C-reactive protein (AUC=0.700). PRS developed and validated in individuals of East Asian descent performed similarly (AUC=0.948). Assuming a prior probability of AS of 10% such as in patients with chronic back pain under 45 years of age, compared with HLA-B27 testing alone, PRS provides higher positive values for 35% of patients and negative predictive values for 67.5% of patients. For PRS, in people of European descent, the maximum positive predictive value was 78.2% and negative predictive value was 100%, whereas for HLA-B27, these values were 51.9% and 97.9%, respectively.
CONCLUSIONS: PRS have higher discriminatory capacity for AS than CRP, sacroiliac MRI or HLA-B27 status alone. For optimal performance, PRS should be developed for use in the specific ethnic groups to which they are to be applied. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  ankylosing; genetic; low back pain; magnetic resonance imaging; polymorphism; spondylitis

Year:  2021        PMID: 34161253     DOI: 10.1136/annrheumdis-2020-219446

Source DB:  PubMed          Journal:  Ann Rheum Dis        ISSN: 0003-4967            Impact factor:   19.103


  8 in total

1.  The Associations of rs1799724 and rs361525 With the Risk of Ankylosing Spondylitis Are Dependent on HLA-B27 Status in a Chinese Han Population.

Authors:  Nan Sheng; Yingying Gao; Hui Li; Wenwen Wang; Linyu Geng; Bo Zhang; Qiang Huang; Xueqin Wang; Lingyun Sun
Journal:  Front Immunol       Date:  2022-04-05       Impact factor: 8.786

2.  Impact of HLA-B27 and Disease Status on the Gut Microbiome of the Offspring of Ankylosing Spondylitis Patients.

Authors:  Matthew L Stoll; Kimberly DeQuattro; Zhixiu Li; Henna Sawhney; Pamela F Weiss; Peter A Nigrovic; Tracey B Wright; Kenneth Schikler; Barbara Edelheit; Casey D Morrow; John D Reveille; Matthew A Brown; Lianne S Gensler
Journal:  Children (Basel)       Date:  2022-04-16

Review 3.  [Axial spondyloarthritis : Update on management based on the interdisciplinary S3 guidelines on axial spondyloarthritis including early forms and ankylosing spondylitis].

Authors:  D Kiefer; J Braun; U Kiltz
Journal:  Z Rheumatol       Date:  2022-02-03       Impact factor: 1.372

Review 4.  Progress in the genetics of uveitis.

Authors:  Xiu-Feng Huang; Matthew A Brown
Journal:  Genes Immun       Date:  2022-04-04       Impact factor: 4.248

5.  Heterogeneity of axial spondyloarthritis: genetics, sex and structural damage matter.

Authors:  Zhixiu Li; Sjef M van der Linden; Muhammad Asim Khan; Heinz Baumberger; Hermine van Zandwijk; Mohammad Kazim Khan; Peter M Villiger; Matthew A Brown
Journal:  RMD Open       Date:  2022-05

6.  Recurrence of axial spondyloarthritis among first-degree relatives in a prospective 35-year-follow-up family study.

Authors:  Sjef M van der Linden; Muhammad Asim Khan; Zhixiu Li; Heinz Baumberger; Hermine van Zandwijk; Mohammad Kazim Khan; Peter M Villiger; Matthew A Brown
Journal:  RMD Open       Date:  2022-07

7.  Immune cell infiltration-related clinical diagnostic model for Ankylosing Spondylitis.

Authors:  Chenxing Zhou; Tuo Liang; Jie Jiang; Zide Zhang; Jiarui Chen; Tianyou Chen; Liyi Chen; Xuhua Sun; ShengSheng Huang; Jichong Zhu; Shaofeng Wu; Xinli Zhan; Chong Liu
Journal:  Front Genet       Date:  2022-09-05       Impact factor: 4.772

Review 8.  The genetic backbone of ankylosing spondylitis: how knowledge of genetic susceptibility informs our understanding and management of disease.

Authors:  Marcus Kenyon; Sinead Maguire; Anna Rueda Pujol; Finbar O'Shea; Ross McManus
Journal:  Rheumatol Int       Date:  2022-08-08       Impact factor: 3.580

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.